Medifast, Inc.
MEDConsumer CyclicalNASDAQPersonal Services · Last scanned Sep 7, 2026
Scan Results
Daily timeframePart of the consumer cyclical sector, Medifast, Inc. (MED) is listed under Personal Services. The company carries a $141.2M market cap, placing it firmly in the micro-cap category. The company offers weight loss, weight management, and healthy living products comprising bars, cereals, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, soups, amino acid blends, whey protein, hot beverages, brownies, and mini meals under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories, as well as daily nutrient packs, including multivitamins, minerals, and omega-3 fatty acid supplements.
Market Cap
$141.2M
Beta
0.73
P/E (TTM)
—
P/E (Fwd)
-45.11
EPS (TTM)
$-2.33
EPS (Fwd)
$-0.28
ROE
-12.4%
ROA
-4.6%
Cash
$169.8M
Total Debt
$27.6M
Free CF
$11.4M
52W Change
-8.6%
Annual Financials
Cash vs Debt
Where MED stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, MED finished 13.94% above its 150-day moving average ($11.12) and 13.53% above its 200-day moving average ($11.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MED overbought or oversold?
At the September 3, 2026 close, MED's RSI(14) was 81.8, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $169.8M in cash and $27.6M in debt, MED maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $11.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -12.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $1.60B (2022) to $385.8M (2025), a 76% decline worth watching.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Medifast, Inc. and its sector.